In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
about
Relevance of genetic alterations in squamous and small cell lung cancer.Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.The role of tumor microenvironment in resistance to anti-angiogenic therapy.FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosis
P2860
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
@en
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
@nl
type
label
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
@en
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
@nl
prefLabel
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
@en
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
@nl
P2093
P2860
P50
P1433
P1476
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models
@en
P2093
Anne Jacquet-Bescond
Federica Guffanti
Giovanna Damia
Laura Ceriani
Marie-Jeanne Pierrat
Mariella Ferrari
Mike F Burbridge
Monique Zangarini
Rosaria Chilà
P2860
P356
10.1016/J.NEO.2016.11.008
P577
2016-12-15T00:00:00Z